Shock Wave vs. On-demand Tadalafil for Erectile Dysfunction

Sponsor
Menoufia University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05199727
Collaborator
(none)
50
1
2
8
6.3

Study Details

Study Description

Brief Summary

The objective of this study is to evaluate the effectiveness and safety of focused Li-ESWT on 25 participants complaining of ED compared to 25 participants complaining of ED on medical treatment on a prospective clinical trial for 12 weeks.

Condition or Disease Intervention/Treatment Phase
  • Device: LI-ESWT
  • Drug: Tadalafil 20Mg Oral Tablet
N/A

Detailed Description

Penile erection is a very complex process which requires a delicate and coordinated equilibrium among the neurological, vascular and the tissue compartments. It also includes arterial dilation, trabecular smooth muscle relaxation, and activation of the corporeal veno occlusive mechanism.Erectile dysfunction is defined as persistent inability to achieve or maintain the erection that is sufficient to permit satisfactory sexual intercours. It has a multifactorial pathogenesis, one of them is vasculogenic ED that occurs due to diseases such as diabetes mellitus, hypertension, hyperlipidemia, smoking, or vascular occlusive disease.

ED is also the most commonly treated sexual disorder and it affects approximately 20% of adult males over the age of 20. Nowadays, there are several treatment solutions for patients with ED, either non-invasive or invasive but the phosphodiesterase 5 inhibitors are still the first-line therapy for ED.

However, PDE5-Is effect is limited due to their inability to improve penile blood flow for a time period that is sufficient to allow optimal oxygenation and recovery of Cavernosal vasculature. Also, they cannot improve spontaneous erections. Moreover, several patients ranging from 40% to 50% will not respond to drug therapy even after optimization approaches such as treatment combinations have been implemented.

Also, it was proven that the effect of long-term daily use of PDE5-Is on endothelial function has induced a short-term improvement in erectile function but probably not a longstanding one.

Another option for ED patients is the use of intracavernosal injections which is considered the second line of treatment. Although PDE5-Is and intracavernosal injections are effective and safe vasodilating agents, they are unable to alter the underlying predominant pathology in patients with vasculogenic ED (eg, cavernosal artery insufficiency).

Other options include the use of intraurethral injections, or vacuum constrictive devices that could serve as salvage therapy for patients who failed to respond to PDE5-Is. If the previous options failed or not preferred by the patient, penile prosthesis implantation would be the last resort treatment for ED.

Many trials were done to find a new treatment modality that would provide a rehabilitative or curative effect for ED. This modality should affect the endothelial function and improve penile hemodynamics. One of these modalities was low-intensity extracorporeal shockwave therapy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Comparison of the Efficacy and Safety of Low Intensity Extracorporeal Shock Wave Therapy Versus On-demand Tadalafil for Erectile Dysfunction
Actual Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Mar 1, 2022
Anticipated Study Completion Date :
May 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Shockwave group

This group will receive 6 sessions (2 per week) with average 6,000 shocks per session with the PiezoWave2 unit

Device: LI-ESWT
Low intenisty shockwave therapy newly used for treatment of erectile dysfunction by applying 6 sessions on 3 weeks (2 sessions /week)
Other Names:
  • Shockwave therapy
  • Active Comparator: Medical Treatment Group

    This group will receive self-administered Tadalafil on-demand

    Drug: Tadalafil 20Mg Oral Tablet
    Patients on this arm will allocate on on-demand tadalafil 20 mg for treatment of ED

    Outcome Measures

    Primary Outcome Measures

    1. Erectile function assessed by International Index of Erectile Function-5 [3 months]

      We will asessess erectile function using International Index of Erectile Function-5 (IIEF-5) where scores ≤6, severe; 8-16, moderate; 17-21, mild; and 22-25, none.

    Secondary Outcome Measures

    1. Erection hardness score [3 months]

      We will assess the Erection Hardness Score (EHS) was based on self-estimated rigidity, categorized using a scale of 1- 4: (1) the penis is larger but not hard, (2) the penis is hard but not hard enough for penetration, (3) the penis is hard enough for penetration but not completely hard, and (4) the penis is completely hard and fully rigid for coitus

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    25 Years to 60 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Male patients

    • ED at least for 6 months

    • vasculogenic ED

    • from 25-60 years old

    Exclusion Criteria:
    • psychological patents

    • neurological patients

    • younger than 25 years old

    • older than 60 years old

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Menoufia University Cairo Egypt 32632

    Sponsors and Collaborators

    • Menoufia University

    Investigators

    • Study Director: fouad zanaty, professor, Menoufia University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Hosam Kotb, Principal investigator, Menoufia University
    ClinicalTrials.gov Identifier:
    NCT05199727
    Other Study ID Numbers:
    • 5/2021UROL9
    First Posted:
    Jan 20, 2022
    Last Update Posted:
    Jan 20, 2022
    Last Verified:
    Jan 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Hosam Kotb, Principal investigator, Menoufia University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 20, 2022